Overview on Acquired Partial Lipodystrophy: Review Article | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 70, Volume 91, Issue 1, April 2023, Page 4242-4245 PDF (413.35 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2023.296194 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Raghad Awad Alraddadi 
| ||||
| Abstract | ||||
| Background: Acquired partial lipodystrophy (APL), an uncommon form of the disease, is characterised by a gradual onset of bilaterally symmetrical subcutaneous fat loss from the face, neck, upper extremities, thorax, and abdomen while sparing the lower limbs. About 20% of those with APL also have autoimmune disorders, especially membranoproliferative glomerulonephritis (MPGN). Additionally, the majority of patients have low levels of serum complement 3 (C3), and some of them also have C3 nephritic factor. Metabolic issues are uncommon. Objective: This review aimed to provide an overview of acquired partial lipodystrophy's prevalence, pathophysiology, diagnosis, and treatment. Methods: We scoured medical journals and databases including PubMed, Google Scholar, and Science Direct for information on: Acquired partial lipodystrophy, Pathophysiology, Diagnosis and Treatment. Between 2003 and 2022, however, only the latest or most comprehensive study was considered. The authors also assessed the usefulness of references drawn from similar books. Documents written in languages other than English have been overlooked because of lack of funding to translate them. Unpublished articles, oral talks, conference abstracts, and dissertations were all generally agreed upon not to constitute valid scientific investigation. Conclusion: Hyperglycemia and hypertriglyceridemia that do not improve with medication or excessively high insulin dosages may be important signs of lipodystrophy in the clinical environment. It is important to emphasise that these criteria have not been prospectively tested, despite the fact that efforts to introduce these criteria to various treatment contexts (private, academic, government, and others) may be significant for figuring out the true incidence of these diseases. By enhancing lipodystrophy identification and increasing public awareness of the ailment, it will be simpler to ensure that patients with the condition receive the proper care. Acquiring metabolic control and treating aesthetic issues brought on by fat loss are the main goals of therapeutic care for patients with acquired lipodystrophy. | ||||
| Keywords | ||||
| lipodystrophy; acquired; glomerulonephritis; metabolic disease | ||||
|
Statistics Article View: 169 PDF Download: 383 |
||||
